Halozyme Therapeutics (HALO) Proxy filing summary

Executive summary

• Annual meeting scheduled for May 5, 2026, with voting available online and virtually.

• Shareholders are encouraged to review proxy materials and vote by May 4, 2026.

Voting matters and shareholder proposals

• Election of Class I Directors, with nominees Bernadette Connaughton and Matthew L. Posard.

• Advisory vote to approve compensation of named executive officers.

• Ratification of Ernst & Young LLP as independent registered public accounting firm for fiscal year ending December 31, 2026.

• Additional business may be addressed as appropriate during the meeting.

Board of directors and corporate governance

• Board recommends voting in favor of all proposals and director nominees.